Caribou Biosciences (NASDAQ:CRBU) and Larimar Therapeutics (NASDAQ:LRMR) Financial Survey

Caribou Biosciences (NASDAQ:CRBU) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Analyst Ratings

This is a summary of current ratings for Caribou Biosciences and Larimar Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	1	0	3	1	2.80
Larimar Therapeutics	1	0	6	3	3.10

Caribou Biosciences presently has a consensus price target of $7.75, indicating a potential upside of 372.56%. Larimar Therapeutics has a consensus price target of $11.67, indicating a potential upside of 188.07%. Given Caribou Biosciences’ higher possible upside, equities analysts clearly believe Caribou Biosciences is more favorable than Larimar Therapeutics.

Institutional & Insider Ownership

77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are held by institutional investors. 8.5% of Caribou Biosciences shares are held by company insiders. Comparatively, 4.0% of Larimar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Caribou Biosciences and Larimar Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-1,030.42%	-89.11%	-62.47%
Larimar Therapeutics	N/A	-137.39%	-97.65%

Risk & Volatility

Caribou Biosciences has a beta of 2.38, suggesting that its share price is 138% more volatile than the S&P 500. Comparatively, Larimar Therapeutics has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500.

Valuation & Earnings

This table compares Caribou Biosciences and Larimar Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$10.04 million	17.52	-$148.12 million	($1.08)	-1.52
Larimar Therapeutics	N/A	N/A	-$165.67 million	($1.95)	-2.08

Caribou Biosciences has higher revenue and earnings than Larimar Therapeutics. Larimar Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Caribou Biosciences beats Larimar Therapeutics on 9 of the 14 factors compared between the two stocks.

About Caribou Biosciences

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

About Larimar Therapeutics

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.